MIAMI BEACH, Fla., Nov. 9, 2011 /PRNewswire/ -- Biotech developer Divine Skin Inc. (OTC Bulletin Board: DSKX) which has been expanding the topical hair-growth segment, is rolling out that market's newest, most potent, only customizable system, Polaris API Solution 9, to be supplied by physicians for treatment through multiple methods of action. With well-established materials like minoxidil sulfate, finasteride, alfatradiol, and other active ingredients, Polaris API Solution 9 is the most complete solution that can be used for hair loss, either by prescription or over the counter configured to the individual needs of the patient by physicians. The current sales leader contains only 5% minoxidil in a standard carrier. "We are launching a new category," declared CEO Daniel Khesin, speaking on a conference call with investors. "We expect this line to change the game and to offer a powerful new tool for dermatologists that can really make a difference in their approach to treatment." Half of all men will experience some hair loss by age 50, and they can only purchase the customized Polaris product through physicians, who can create the potent mix of active pharmaceutical ingredients (API). Divine Skin, which posted revenue of $5.4 million in 2010 — up 55 percent over the previous year — creates a major new revenue stream with Polaris API Solution 9, and stockholders expect to benefit for several years. In published clinical trials, each major component of the new API — minoxidil sulfate, finasteride, and alfatradiol — has proven to inhibit androgenic alopecia (male pattern baldness) effectively. The system also includes other auxiliary agents like apple polyphenol, copper peptides, nutrients, and conditioners to enhance the formula further. "With very few options available," says Khesin, "Polaris API Solution 9 is by far the most viable option for physicians to quickly and easily customize the ideal treatment for their patients. We expect everyone to do very well with this product."